Clinical, ethical, and quality-of-life outcomes in unresectable hepatocellular carcinoma: the LEAP-012 trial.
0/5 보강
APA
Sherry AD, Dudzinski SO, Ludmir EB (2025). Clinical, ethical, and quality-of-life outcomes in unresectable hepatocellular carcinoma: the LEAP-012 trial.. Lancet (London, England), 406(10504), 693-694. https://doi.org/10.1016/S0140-6736(25)01440-0
MLA
Sherry AD, et al.. "Clinical, ethical, and quality-of-life outcomes in unresectable hepatocellular carcinoma: the LEAP-012 trial.." Lancet (London, England), vol. 406, no. 10504, 2025, pp. 693-694.
PMID
40818847 ↗
같은 제1저자의 인용 많은 논문 (3)
- The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer.
- Setting the TRAP for Oligoprogressive Prostate Cancer: The Impetus for Prospective Evidence.
- Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial.